Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Gemcitabine

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

76 API Suppliers, 31 USDMF, 25 CEP/COS, 12 JDMF, 12 EU WC, 31 KDMF, 18 NDC API, 43 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

301 Drugs in Development

301 Drugs in Development

INTERMEDIATES

19 Intermediate Suppliers

19 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

245 FDF Dossiers, 88 FDA Orange Book, 89 Europe, 4 Canada, 4 Australia, 21 South Africa, 39 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 200MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAVENOUS - EQ 1200MG BASE/120ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1300MG BASE/130ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1400MG BASE/140ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1500MG BASE/150ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1600MG BASE/160ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1700MG BASE/170ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1800MG BASE/180ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1900MG BASE/190ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 2000MG BASE/200ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 13 SPI Pharma, 1 Faran Shimi Pharmaceutical, 1 Gangwal Healthcare, 1 Pfanstiehl, 1 Actylis, 1 BASF, 2 Gangwal Chemicals, 1 Ingredion Pharma Solutions, 2 Kerry, 2 Microlex e.U, 1 Pluviaendo, 3 Roquette, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

17 Fillers, Diluents & Binders, 11 Chewable & Orodispersible Aids, 10 Taste Masking, 10 Direct Compression, 7 Disintegrants & Superdisintegrants, 5 Co-Processed Excipients, 5 Parenteral, 3 Granulation, 1 Solubilizers, 1 Thickeners and Stabilizers

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 103 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 69 Regulatory FDF Prices, 2 Annual Reports

MARKET PLACE

17 APIs, 9 FDF Dossiers, 2 Intermediates

PATENTS & EXCLUSIVITIES

10 US Patents

10 US Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 1 USP, 3 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
28/03/2025	Evonik	Germany	Boryeong Co., Ltd.	20071228-86-D-24-04	Gemcitabine hydrochloride	2007-12-28	Evonik Corporation	U.S.A	Tippecanoe Laboratories Lafayette, Indiana, USA (1650 Lilly Road)
28/03/2025	Dr. Reddy\'s Laboratories	India	Korea United Pharmaceutical Co., Ltd.	20070928-86-D-51-03(3)	Gemcitabine hydrochloride	2012-05-18	Dr. Reddy's Laboratories Limited	India	CTO - Unit-I, Plot Nos. 137,138,145 & 146, SV Co-Op, Industrial Estate, Bollaram Village, Jinnaram Mandal, Sangareddy District, Telangana - 502 325, INDIA

Gemcitabine

Gemcitabine

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

76 API Suppliers

31 USDMF

25 CEP/COS

12 JDMF

12 EU WC

31 KDMF

18 NDC API

43 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

301 Drugs in Development

INTERMEDIATES

19 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

245 FDF Dossiers

88 FDA Orange Book

89 Europe

4 Canada

4 Australia

21 South Africa

39 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 200MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;INTRAVENOUS - EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

13 SPI Pharma

1 Faran Shimi Pharmaceutical

1 Gangwal Healthcare

1 Pfanstiehl

1 Actylis

1 BASF

2 Gangwal Chemicals

1 Ingredion Pharma Solutions

2 Kerry

2 Microlex e.U

1 Pluviaendo

3 Roquette

1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

17 Fillers, Diluents & Binders

11 Chewable & Orodispersible Aids

10 Taste Masking

10 Direct Compression

7 Disintegrants & Superdisintegrants

5 Co-Processed Excipients

5 Parenteral

3 Granulation

1 Solubilizers

1 Thickeners and Stabilizers

DIGITAL CONTENT

2 Data Compilation #PharmaFlow

103 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions

69 Regulatory FDF Prices

2 Annual Reports

MARKET PLACE

17 APIs

9 FDF Dossiers

2 Intermediates

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 200MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons